{"id":"NCT00564850","sponsor":"Ipsen","briefTitle":"Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty","officialTitle":"Phase III, Multicentre, Non-comparative, Open and Single Stage Study to Assess the Efficacy and Safety of Pamoate of Triptorelin 11.25 MG in Children With Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2007-11-28","resultsPosted":"2011-12-01","lastUpdate":"2022-10-12"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Precocious Puberty"],"interventions":[{"type":"DRUG","name":"Triptorelin pamoate 11.25mg (Decapeptyl® SR)","otherNames":[]}],"arms":[{"label":"Triptorelin pamoate 11.25mg (Decapeptyl® SR)","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the efficacy of triptorelin 11.25 mg pamoate in the delay of premature onset of puberty in girls less than 9 years and boys less than 10 years. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection with triptorelin 11.25 mg.","primaryOutcome":{"measure":"Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L","timeFrame":"3 months after the first injection of triptorelin pamoate 11.25 mg","effectByArm":[{"arm":"Triptorelin Pamoate 11.25 mg","deltaMin":31,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":18,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":37},"commonTop":["Abdominal pain","Injection site pain","Hot flush"]}}